23andMe is using its database of more than 850,000 customers' DNA to try to discover new drugs that can cure a wide range of diseases. » Read More
Following are the day’s biggest winners and losers. Find out why shares of Yum! Brands and Piper Jaffray popped while Microsoft and Abbott Labs dropped.
Oh, the fun the late-night comics could have with this one. The makers of the little blue pill are a little red-faced on the Emerald Isle.
With stocks rallying for 5 weeks in a row now, dividend yields are falling back to Earth. The average dividend yield of the Dow 30 has fallen over 25% since the rally began in early March. See how the 30 companies in the Dow compare.
BlackRock's Bob Doll says the investor needs to realize where we are in both the economic cycle and the market cycle, and he has some suggestions about where to re-adjust a portfolio. (Part One)
BlackRock's Bob Doll says the investor needs to realize where we are in both the economic cycle and the market cycle, and he has some suggestions about where to re-adjust a portfolio. (Part Two)
Cramer makes the call on viewers' favorite stocks.
A drug from Novartis has won U.S. approval as a treatment for patients with kidney cancer that has returned after treatment with older drugs.
At the start of the month, General Electric was falling fast and the company that once boasted a half trillion dollar market cap, was at risk of falling out of the Top 20 biggest companies in the S&P 500. In less than a month, that has changed significantly.
Despite the drawback in stocks this morning, Bill Spiropoulous of CoreStates Capital Advisors told CNBC that the market recovery “is in full swing” — but Joe Heider of Dawson Wealth Management said investors “can’t call the bottom” yet. Both had investment recommendations.
The Pit Boss is seeing explosive options action in a drug stock. Find out which one!
The economy may be headed toward a recovery sometime in the third or fourth quarter, said Hugh Johnson of Johnson Illington Advisors.
M&A expert Howard Lanser reveals the next sector where he expects to see a big uptick in takeovers!
The Dow fell on Thursday largely due to concerns that the Federal Reserve's latest efforts to battle the recession are too costly and untested...
Between stocks rallying and recent dividend cuts by companies like GE and Alcoa, average dividend yields in the S&P 500 have fallen. Here are some of the details.
Pfizer announced this morning that it's raising the income levels for uninsured people to qualify for cheaper or free drugs because of the bad economy.
Even in this anemic market, it appears the urge to merge is alive and well.
Scientific and medical journals like to keep their distance from the business side of things. That's why I think it's worth noting that a "Perspective" piece--think of it as kind of a newspaper Op-Ed--in "The New England Journal of Medicine" starts by mentioning Pfizer's stock price and its recent proposed acquisition of Wyeth.
Following are the day’s biggest winners and losers. Find out why shares of Barclays and DuPont popped while Pfizer and General Motors dropped.
This was a very constructive week, the best weekly advance for the Dow and the S&P 500 since November.
What's been happening in the market has been enough to turn some people off on stocks, but not Stephen Mauzy. If anything, he's worried that the down market won't last long enough.